James H. Stanker - Sep 30, 2022 Form 4/A - Amendment Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Chief Financial Officer
Signature
/s/ James H. Stanker by Michael B. Kirwan, as Attorney-in-Fact
Stock symbol
PCSA
Transactions as of
Sep 30, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
10/5/2022, 04:40 PM
Date Of Original Report
Oct 3, 2022
Previous filing
Aug 9, 2022
Next filing
Jan 4, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Award $0 -13K -3.67% $0.00 340K Sep 30, 2022 Common Stock 13K $0.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.
F2 Previous filing inadvertently underreported derivative securities beneficially owned by the reporting person.